Leadership and Continuing Research
Under the Innogentics brand, Fujirebio first developed cerebrospinal fluid (CSF) biomarkers over 30 years ago. These have evolved over time from purely research-use-only biomarkers to specialized in vitro diagnostic testing products. Where once they were solely used by early adopters, they are now an essential part of routine AD testing in many parts of the world.
Today, Fujirebio is the only company with a comprehensive line of Alzheimer’s products capable of running on automated systems. Building on this legacy, we have achieved a historic milestone: the first FDA-cleared blood-based biomarker test for Alzheimer’s disease assessment—the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test. This breakthrough eliminates the need for invasive CSF collection, offering clinicians and patients a simpler, more accessible way to detect amyloid pathology.
While this marks a new era in Alzheimer’s diagnostics, we recognize the scope of what is still to accomplish. We continue to invest in the development of innovative biomarkers and technologies to advance early and accurate diagnosis worldwide.
Diagnostic Tools for Alzheimer’s Disease
Learn about our high-quality biomarkers for Alzheimer's disease assessment such as the FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio & Lumipulse® G β-Amyloid Ratio (1-42/1-40) CSF tests and other BBM and CSF tests for Research Use Only (RUO), not for use in diagnostic procedures. Visit our diagnostic tools for Alzheimer's disease site for more information.
Medical Education
The following educational programs are made possible through the generous support of Fujirebio.
PRATICAL APPLICATIONS | Complimentary 3-Part Live Webinar Series
- Part 1: Demystifying Alzheimer's Blood Biomarkers: What Every Clinician Needs to Know
- 1 P.A.C.E.® credit-hour will be provided for this program. Fujirebio is approved as a provider of CE programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.
- This program is approved for 1 Florida Laboratory CE credit. Florida Board of Clinical Laboratory Personnel approved number: 50-12563
EARN FREE CE CREDITS | On Demand
- Navigating the Use of Fluid Biomarker Testing for Early Disease Identification and Management
- Physician Credit: up to 1.0 AMA PRA Category 1 Credits™,
- Nursing Credit: up to 1.0 ANCC Nursing Contact Hours,
- Physician Assistant Credit: up to 1.0 AAPA Category 1 CME Credit,
- Maintenance of Certification Credit: up to 1.0 MOC point in the ABIM MOC program
MEDICAL EDUCATION | On Demand
- Pathologies and the Use of Cerebrospinal-Fluid-Based Biomarkers in Alzheimer's Disease
- THIS ACTIVITY HAS EXPIRED FOR CREDITS
Global Fujirebio Neuro Center of Excellence
Our global Fujirebio Neuro Center of Excellence is a hub for our worldwide team of researchers into neurodegenerative diseases. It functions as a research and development lab focused on developing diagnostic solutions, but it is more than that… it is also a meeting point, a forum for experts from all around the globe to share knowledge. This is a center for partnership and collaboration, a place for research, development and manufacture, a meeting place for brilliant minds and a starting point for great ideas to find the next generation of diagnostics.
NExT - Neuro Expert Toolbox
As early diagnosis and personalized treatment become increasingly important, Fujirebio brings unique value through its comprehensive Neuro Expert Toolbox (NExT).
This innovative concept enables partners and customers to access Fujirebio’s expertise at every stage of biomarker development – from initial concept to validated diagnostic solutions.
Partnering for Progress
While one of the goals of our global Fujirebio Neuro Center of Excellence is to develop new testing solutions for our own analytical platforms, such as Lumipulse®, we also apply our know-how to our partners’ systems as well. We provide a variety of possible collaborations, including supply of fundamental base materials for research and development. Our goal is to make our tools for the diagnosis of Alzheimer’s available globally, by working with our partners to bring raw materials and products to the diagnostic market.
